- Home
- BCDA vs LSBPW Comparison
BCDA vs LSBPW Comparison
Compare BCDA & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- LSBPW
- Stock Information
- Founded
- BCDA N/A
- LSBPW N/A
- Country
- BCDA United States
- LSBPW China
- Employees
- BCDA N/A
- LSBPW 758
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- LSBPW Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- LSBPW Health Care
- Exchange
- BCDA Nasdaq
- LSBPW Nasdaq
- Market Cap
- BCDA 7.9M
- LSBPW N/A
- IPO Year
- BCDA N/A
- LSBPW N/A
- Fundamental
- Price
- BCDA $2.68
- LSBPW $0.07
- Analyst Decision
- BCDA Strong Buy
- LSBPW
- Analyst Count
- BCDA 1
- LSBPW 0
- Target Price
- BCDA $25.00
- LSBPW N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- LSBPW N/A
- Earning Date
- BCDA 11-06-2024
- LSBPW N/A
- Dividend Yield
- BCDA N/A
- LSBPW N/A
- EPS Growth
- BCDA N/A
- LSBPW N/A
- EPS
- BCDA N/A
- LSBPW N/A
- Revenue
- BCDA $428,000.00
- LSBPW N/A
- Revenue This Year
- BCDA $6.92
- LSBPW N/A
- Revenue Next Year
- BCDA N/A
- LSBPW N/A
- P/E Ratio
- BCDA N/A
- LSBPW N/A
- Revenue Growth
- BCDA 0.71
- LSBPW N/A
- 52 Week Low
- BCDA $1.96
- LSBPW N/A
- 52 Week High
- BCDA $23.25
- LSBPW N/A
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- LSBPW N/A
- Support Level
- BCDA $2.39
- LSBPW N/A
- Resistance Level
- BCDA $2.90
- LSBPW N/A
- Average True Range (ATR)
- BCDA 0.18
- LSBPW 0.00
- MACD
- BCDA -0.00
- LSBPW 0.00
- Stochastic Oscillator
- BCDA 53.70
- LSBPW 0.00
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About LSBPW LakeShore Biopharma Co. Ltd
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.